Darzalex Faspro’s approval for smoldering multiple myeloma could allow for earlier intervention and reduce the risk of ...

Multiple myeloma diagnosis integrates blood tests, genetic assessments, and imaging to guide personalized treatment and patient engagement. Smoldering multiple myeloma involves active surveillance to ...

Bristol Myers Squibb’s (BMS’s) investigational cereblon E3 ligase modulator iberdomide has shown promise in a mid-stage endpoint of a multiple myeloma trial. The ongoing Phase III EXCALIBER-RRMM study ...

Support for first and only high-risk smouldering multiple myeloma treatment came from positive phase 3 trial results ...

In patients with symptomatic multiple myeloma, renal impairment leading to acute kidney injury (AKI) is a common complication ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Johnson & Johnson received U.S. Food and Drug ...

US FDA approves Darzalex Faspro for adult patients with high-risk smouldering multiple myeloma: San Diego Monday, November 10, 2025, 17:00 Hrs [IST] Halozyme Therapeutics, Inc. (H ...

The treatment of relapsed/refractory multiple myeloma dramatically changed in recent years with the emergence of therapies ...

First clinical data disclosure for CB-011 highlights its potential as a best-in-class allogeneic CAR-T cell therapy for relapsed or refractory ...

Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed the last patient, last visit in its ongoing ...

Stage 1 multiple myeloma features low beta-2 microglobulin, high albumin, and no organ damage, often detected incidentally. Diagnosis involves blood, urine, imaging tests, and bone marrow biopsy to ...